Laboratorios Rovi - Public Comps and Valuation Multiples

Laboratorios Rovi Overview

About Laboratorios Rovi

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Founded

1946

HQ

Employees

2.2K+

Website

rovi.es

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $856M

LTM EBITDA $237M

EV

$3.9B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Laboratorios Rovi Financials

As of September 2025, Laboratorios Rovi reported last 12-month revenue of $856M and EBITDA of $237M.

In the same period, Laboratorios Rovi generated $550M in LTM gross profit and $150M in net income.

See Laboratorios Rovi valuation multiples based on analyst estimates

Laboratorios Rovi P&L

In the most recent fiscal year, Laboratorios Rovi reported revenue of $890M and EBITDA of $242M.

Laboratorios Rovi expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Laboratorios Rovi valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$856M	XXX	$890M	XXX	XXX	XXX
Gross Profit	$550M	XXX	$558M	XXX	XXX	XXX
Gross Margin	64%	XXX	63%	XXX	XXX	XXX
EBITDA	$237M	XXX	$242M	XXX	XXX	XXX
EBITDA Margin	28%	XXX	27%	XXX	XXX	XXX
EBIT	$190M	XXX	$209M	XXX	XXX	XXX
EBIT Margin	22%	XXX	24%	XXX	XXX	XXX
Net Profit	$150M	XXX	$160M	XXX	XXX	XXX
Net Margin	18%	XXX	18%	XXX	XXX	XXX
Net Debt	XXX	XXX	$82.9M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Laboratorios Rovi including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $856M. EBITDA for the last twelve months was $237M. In the most recent fiscal year, Laboratorios Rovi achieved $890M in revenue and $242M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$856M	Analyst estimates available to subscribers	$890M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$550M	Analyst estimates available to subscribers	$558M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	64.3% gross margin	Analyst estimates available to subscribers	62.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$237M	Analyst estimates available to subscribers	$242M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	27.7% EBITDA margin	Analyst estimates available to subscribers	27.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$190M	Analyst estimates available to subscribers	$209M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	22.2% EBIT margin	Analyst estimates available to subscribers	23.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$150M	Analyst estimates available to subscribers	$160M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	17.6% net profit margin	Analyst estimates available to subscribers	17.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$82.9M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Laboratorios Rovi

This financial data table provides comprehensive performance metrics for Laboratorios Rovi, a company based in Spain. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Laboratorios Rovi generated $856M in revenue over the last twelve months.
The company achieved $237M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $550M.
Net income over the last twelve months reached $150M.

Fiscal Year Performance

In the most recent fiscal year, Laboratorios Rovi reported $890M in total revenue.
Fiscal year EBITDA was $242M.
The company maintained a gross profit margin of 62.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 27.2%.
Net profit margin reached 17.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Laboratorios Rovi. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Laboratorios Rovi Stock Performance

Laboratorios Rovi has current market cap of EUR 3.2B (or $3.8B), and EV of EUR 3.3B (or $3.9B).

Market Cap Evolution

Laboratorios Rovi Stock Data

As of October 30, 2025, Laboratorios Rovi's stock price is EUR 63 (or $74).

See Laboratorios Rovi trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.9B	$3.8B	XXX	XXX	XXX	XXX	$2.88

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Laboratorios Rovi Valuation Multiples

Laboratorios Rovi's trades at 4.3x EV/Revenue multiple, and 16.0x EV/EBITDA.

See valuation multiples for Laboratorios Rovi and 15K+ public comps

Laboratorios Rovi Financial Valuation Multiples

As of October 30, 2025, Laboratorios Rovi has market cap of $3.8B and EV of $3.9B.

Equity research analysts estimate Laboratorios Rovi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Laboratorios Rovi has a P/E ratio of 25.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$3.8B	XXX	$3.8B	XXX	XXX	XXX
EV (current)	$3.9B	XXX	$3.9B	XXX	XXX	XXX
EV/Revenue	4.5x	XXX	4.3x	XXX	XXX	XXX
EV/EBITDA	16.3x	XXX	16.0x	XXX	XXX	XXX
EV/EBIT	20.4x	XXX	18.5x	XXX	XXX	XXX
EV/Gross Profit	7.0x	XXX	n/a	XXX	XXX	XXX
P/E	25.1x	XXX	23.6x	XXX	XXX	XXX
EV/FCF	28.5x	XXX	43.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Laboratorios Rovi Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Laboratorios Rovi Margins & Growth Rates

Laboratorios Rovi's last 12 month revenue growth is 11%

Laboratorios Rovi's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Laboratorios Rovi's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Laboratorios Rovi's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Laboratorios Rovi and other 15K+ public comps

Laboratorios Rovi Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	11%	XXX	5%	XXX	XXX	XXX
EBITDA Margin	28%	XXX	27%	XXX	XXX	XXX
EBITDA Growth	18%	XXX	-9%	XXX	XXX	XXX
Rule of 40	41%	XXX	38%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	56%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	39%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial